Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL C UBA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1578540860
CMS profile
206711
Location
FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,950.48

205 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,950.48 205

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL C UBA

NPI 1578540860 · CMS profile ID 206711

Allopathic & Osteopathic Physicians / Internal Medicine

FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578540860?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL C UBA, NPI 1578540860, CMS profile ID 206711. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578540860?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DANIEL C UBA, NPI 1578540860, CMS profile ID 206711. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578540860?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DANIEL C UBA, NPI 1578540860, CMS profile ID 206711, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 205 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578540860?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

205 matching records · $2,950.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 205 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 205.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $8.8404/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811554964 CMS
AstraZeneca Pharmaceuticals LP $15.9404/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829593695 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.1304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850191227 CMS
GlaxoSmithKline, LLC. $15.1204/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803066929 CMS
AstraZeneca Pharmaceuticals LP $11.0804/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829540677 CMS
Novo Nordisk Inc $8.2903/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811554959 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.6803/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850233069 CMS
Novartis Pharmaceuticals Corporation $15.6803/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813328373 CMS
AbbVie Inc. $21.4803/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796183963 CMS
GlaxoSmithKline, LLC. $16.3503/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802905659 CMS
Novo Nordisk Inc $8.2903/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811244065 CMS
Amgen Inc. $11.5603/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826319017 CMS
AstraZeneca Pharmaceuticals LP $15.1103/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829737555 CMS
Nestle HealthCare Nutrition Inc. $23.0803/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820967543 CMS
Novo Nordisk Inc $8.2903/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811663061 CMS
Esperion Therapeutics, Inc. $23.7203/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838426905 CMS
GlaxoSmithKline, LLC. $15.6103/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803198821 CMS
Novo Nordisk Inc $8.9603/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094459 CMS
Novo Nordisk Inc $6.7703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094453 CMS
AbbVie Inc. $15.7703/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796183961 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.2003/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763700792 CMS
Paratek Pharmaceuticals, Inc. $15.1203/05/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 813532793 CMS
AstraZeneca Pharmaceuticals LP $14.8103/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830009817 CMS
Eyevance Pharmaceuticals LLC $15.7503/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807288801 CMS
Hikma Pharmaceuticals USA $15.7503/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 808537597 CMS
PFIZER INC. $15.0603/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833450095 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.9203/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850331077 CMS
SCILEX PHARMACEUTICALS INC. $22.9502/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846507847 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.9602/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850294971 CMS
GlaxoSmithKline, LLC. $16.7502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803003989 CMS
Novo Nordisk Inc $6.7702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810872309 CMS
Esperion Therapeutics, Inc. $16.5902/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838426897 CMS
Esperion Therapeutics, Inc. $3.1702/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838426899 CMS
AbbVie Inc. $29.9602/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796183959 CMS
Novo Nordisk Inc $7.4402/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811244123 CMS
Novo Nordisk Inc $7.4402/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811392407 CMS
Novo Nordisk Inc $6.3202/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811757177 CMS
PFIZER INC. $15.0202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832602081 CMS
Novo Nordisk Inc $7.2502/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810872301 CMS
SANOFI-AVENTIS U.S. LLC $14.6902/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843519047 CMS
Amarin Pharma Inc. $23.4902/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815037367 CMS
Esperion Therapeutics, Inc. $22.7302/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838426891 CMS
AstraZeneca Pharmaceuticals LP $12.7101/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830191693 CMS
Novo Nordisk Inc $11.1601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811244117 CMS
GlaxoSmithKline, LLC. $15.6001/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801619085 CMS
Amgen Inc. $19.8101/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825240305 CMS
Lilly USA, LLC $10.8801/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819052619 CMS
SANOFI-AVENTIS U.S. LLC $16.3001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843519041 CMS
GlaxoSmithKline, LLC. $15.3701/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802725317 CMS
Novo Nordisk Inc $13.2001/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094445 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,677.51 219
PY2020 $1,953.22 139
PY2021 $2,950.48 205
PY2022 $2,953.01 168
PY2023 $4,791.32 193
PY2024 $3,045.02 117
PY2025 $2,072.54 122

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $678,672.13 11
PY2024 Recipient $99,780.00 1
PY2024 Principal investigator $372,920.00 13
PY2023 Principal investigator $18,987.84 5
PY2022 Principal investigator $7,788.32 4
PY2021 Principal investigator $2,970.75 7
PY2020 Principal investigator $7,452.25 7
PY2019 Principal investigator $55,394.72 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $870.52 09/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187878569
Principal investigator 1 Eli Lilly and Company $170,084.00 08/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187876515
Principal investigator 1 Eli Lilly and Company $165.00 04/30/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878383
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $4,545.23 04/24/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187877205
Principal investigator 1 Eli Lilly and Company $339.50 03/26/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187880543
Principal investigator 1 Eli Lilly and Company $8,432.94 02/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876747
Principal investigator 1 Eli Lilly and Company $405.00 01/31/2025 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187890980
Principal investigator 1 Eli Lilly and Company $10,324.96 01/17/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187877277
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,749.99 01/15/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185541048
Principal investigator 1 Eli Lilly and Company $49,590.99 01/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187878357
Principal investigator 1 Eli Lilly and Company $415,164.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882742